Overview
Antibiotic-resistant bacterial pathogens have been a rising threat to human health for several years. Effectiveness of many antibacterial agents has declined worldwide limiting physicians' options to treat serious infections. Adding to the threat is a decline in development of new and novel antibiotics that target resistant pathogens by the pharmaceutical industry. Antibiotic drug resistance has a significant impact on mortality and contributes heavily to healthcare system costs worldwide. The World Health Organization has stated that antibiotic resistance is one of the greatest healthcare challenges for the future.
Cempra is focused on developing differentiated antibiotics to confront the rising threat of antibiotic-resistant pathogens. Two products are in clinical development. CEM-101 is a novel, orally-active, broad-spectrum fluoroketolide that has completed multi dose Phase I clinical studies in healthy subjects and is entering Phase II clinical development. TAKSTATM (CEM-102, sodium fusidate) is an innovative dosing regimen of a product with a long history of safety and efficacy against gram-positive organisms including MRSA. Phase III trials in acute bacterial skin and skin structure infections will begin soon.
Antibiotic-resistant bacterial pathogens have been a rising threat to human health for several years. Effectiveness of many antibacterial agents has declined worldwide limiting physicians' options to treat serious infections. Adding to the threat is a decline in development of new and novel antibiotics that target resistant pathogens by the pharmaceutical industry. Antibiotic drug resistance has a significant impact on mortality and contributes heavily to healthcare system costs worldwide. The World Health Organization has stated that antibiotic resistance is one of the greatest healthcare challenges for the future.
Cempra is focused on developing differentiated antibiotics to confront the rising threat of antibiotic-resistant pathogens. Two products are in clinical development. CEM-101 is a novel, orally-active, broad-spectrum fluoroketolide that has completed multi dose Phase I clinical studies in healthy subjects and is entering Phase II clinical development. TAKSTATM (CEM-102, sodium fusidate) is an innovative dosing regimen of a product with a long history of safety and efficacy against gram-positive organisms including MRSA. Phase III trials in acute bacterial skin and skin structure infections will begin soon.